DANHOF , Sophia

Last name: DANHOF

First name: Sophia

December 15, 2022 (v1)

Publication

Metadata-only

Publisher correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab (Leukemia, (2021), 35, 1, (201-214), 10.1038/s41375-020-0840-y)

García-Guerrero, Estefanía Götz, Ralph Doose, Sören

No description

Uploaded on: March 24, 2023
September 28, 2022 (v1)

Publication

Metadata-only

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

García-Guerrero, Estefanía Götz, Ralph Doose, Sören

Multiple myeloma (MM) is incurable, so there is a significant unmet need for effective therapy for patients with relapsed or refractory disease. This situation has not changed despite the recent approval of the anti-CD38 antibody daratumumab, one of the most potent agents in MM treatment. The efficiency of daratumumab might be improved by...

Uploaded on: March 24, 2023
February 6, 2024 (v1)

Publication

Metadata-only

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells

García-Guerrero, Estefanía Rodríguez-Lobato, Luis G. Sierro-Martínez, Belén

B-cell maturation antigen (BCMA) is the lead antigen for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). A challenge is inter- and intra-patient heterogeneity in BCMA expression on MM cells and BCMA downmodulation under therapeutic pressure. Accordingly, there is a desire to augment and sustain BCMA expression on MM...

Uploaded on: February 11, 2024

DANHOF , Sophia

Recent uploads